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Wilms’ tumour (WT) is an embryonal renal neoplasm and is one
of the commonest solid tumours of childhood, affecting approxi-
mately one in 10 000 children (Coppes et al, 1995). It is a geneti-
cally complex tumour, with multiple genes involved in familial
and sporadic forms (Huff and Saunders, 1993; Hastie, 1994). Only
the WT1 tumour suppressor gene at 11p13 has been cloned, by
virtue of its involvement in the WAGR syndrome (Wilms’ tumour,
Aniridia, Genitourinary abnormalities and mental Retardation), in
which there are chromosomal deletions at 11p13 (Call et al, 1990;
Gessler et al, 1990; Huang et al, 1990). Loss of heterozygosity
(LOH) studies in sporadic tumours have identified other potential
tumour suppressor loci at 11p15 (Ping et al, 1989; Reeve et al,
1989), 16q (Maw et al, 1992), 1p (Grundy et al, 1994), 7p15
(Wilmore et al, 1994) and 11q (Radice et al, 1995). Relaxation of
imprinting at 11p15, leading to biallelic expression of the normally
imprinted gene IGF2, is a common event in sporadic WTs not
showing 11p LOH (Ogawa et al, 1993; Rainier et al, 1993).
Overexpression of IGF2 also occurs in the Beckwith–Wiedemann
syndrome (BWS), which predisposes to WT, and which is associ-
ated with 11p15 partial trisomy, uniparental paternal disomy of
11p15, and imprinting mutations at 11p15 (Reik and Maher, 1997).
Two familial loci have recently been identified at 17q and at 19q
by linkage analysis (Rahman et al, 1996; McDonald et al, 1998).
p53 mutations, 16q LOH and 1p LOH are all associated with a
poor prognosis in WT (Grundy et al, 1994; Malkin et al, 1994;
Lahoti et al, 1996).
Despite the isolation of WT1 and the identification of several
alternate loci, there are still many WTs in which no genetic abnor-
malities have been detected. In WTs showing 11p LOH and/or
WT1 mutations, premalignant lesions associated with the tumours
(nephrogenic rests (Beckwith et al, 1990)) have been shown to
contain identical LOH or mutations (Park et al, 1993; Charles et al,
1998a), implying that further genetic changes are required for
progress to malignancy. Thus in many WTs the initiating genetic
events are still unclear, as are the genetic pathways by which
nephrogenic rests progress to malignancy.
The discovery of cytogenetic abnormalities in syndromes
predisposing to WT, i.e. 11p13 deletions in WAGR syndrome
(Franke et al, 1979), 11p15 partial trisomy and translocations in
BWS (Reik and Maher, 1997), have proved critical for the identifi-
cation of WT genes. We therefore became interested in a patient
who presented with WT, a nephrogenic rest in the contralateral
kidney and an unusual set of congenital abnormalities (bilateral
radial aplasia and other skeletal abnormalities) not previously
associated with WT (Hewitt et al, 1991). This patient had a 
constitutional balanced chromosome translocation; t(1;7)
(q42;p15) (Hewitt et al, 1991). In the patient’s WT, both translo-
cated chromosomes were retained, but an isochromosome 7q was
formed, making the tumour monosomic for 7p and trisomic for 
7q (confirmed by molecular studies) (Wilmore et al, 1994). The
bilateral nature of this patient’s kidney disease, the molecular and
cytogenetic findings, together with 7p LOH in another sporadic
WT, led us to propose that chromosome 7p15 contains a tumour
suppressor gene involved in WT development (Wilmore et al,
1994).
We have now accurately mapped the breakpoint on 7p to a
500 bp region, by fluorescence in situ hybridization (FISH)
analysis with human YAC and cosmid clones, and by higher reso-
lution molecular studies (Reynolds et al, 1996 and unpublished
observations). In order to investigate the potential involvement of
this locus in other WTs, we have used a panel of polymorphic
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breakpoint), to determine the frequency of LOH in this region.
This is the largest study of 7p LOH in WT, and we show that LOH
at 7p occurs in 9% of WTs, and that the common region lost
includes the area disrupted by the t(1;7) translocation.
MATERIALS AND METHODS
Tissues and DNA and RNA extraction
Sixty-one WTs and corresponding normal kidney samples were
collected in Bristol. One patent had WAGR syndrome, one BWS,
two were first cousins and one patient had a constitutional t(1;7)
with skeletal abnormalities (this is patient WT21 in Figure 1)
(Hewitt et al, 1991). All other cases were sporadic with no obvious
genetic predisposition. Eighteen WTs were from Portugal, and
clinical data were not available for these.
Fresh normal kidney and tumour tissues were snap-frozen in
liquid nitrogen and then stored at –70°C. DNA and RNA were
extracted from frozen tissues as described previously (Maitland
et al, 1987). Where fresh tissue was not available, or where the
lesion was too small to be dissected from the gross tumour tissue,
DNA was extracted using microdissection from paraffin sections
(Charles et al, 1998a).
Polymerase chain reaction for LOH
The primers used for polymerase chain reaction (PCR) are shown
in Table 1. One microlitre of purified DNA (0.5 mg ml–1) or 5 ml of
microdissection supernatant were used for each PCR reaction in a
final volume of 25 ml, overlaid with 50 ml mineral oil. The mix
consisted of DNA (as above) in 10 mM Tris–HCl pH 9.0, 1.5 mM
magnesium chloride, 50 mM potassium chloride, 0.1% Triton
X-100, 0.01% gelatin, 1 mM each of forward and reverse primer
and 0.25 units Supertaq polymerase (HT Biotechnology Ltd,
Cambridge, UK). Tubes were denatured for 3 min at 94°C,
followed by 40 cycles of 94°C for 1 min, 55°C for 1 min and 72°C
for 1 min. PCR products were run on 6 or 8% non-denaturing
polyacrylamide gels and visualized by ethidium bromide staining
(Mellersh and Sampson, 1993). All PCRs were set up using
aerosol-resistant tips, in a separate room away from where 
products were analysed. Negative controls were included in each
reaction set, and results were repeated if contamination was
detected in these.
Loss of imprinting
Loss of imprinting leading to biallelic expression of IGF2 was
assessed using transcribed polymorphisms in IGF2 RNA, as
described previously (Brown et al, 1996).
Cytogenetic analysis and Southern blotting
These were carried out using standard methods, as described
previously (Wilmore et al, 1994). A minimum of ten metaphases
were analysed per tumour and the abnormalities shown in Figure 1
were found in all cells examined.
RESULTS
LOH and other genetic changes at 7p
A total of 79 Wilms’ tumours were analysed with a panel of six
polymorphic microsatellite markers on 7p, and 77 (97%) were
informative for at least one of these markers. The markers 
used were previously mapped dinucleotide and tetranucleotide
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Table 1 PCR primers used for LOH studies
Location Marker Repeat Primer sequences (5¢®3¢) Product Reference
type size (bp)
7p22 D7S517 D F: tggagaagccatgtgagt 250 Dib et al, 1996
R: agctgtaattagttgctggtttga
7p15 D7S795 T F: taaatgcctggagtctggag 230 Sheffield et al, 1995
R: tcacagaaacccaatccact
7p15 D7S2211 T F: gataggtgcagcaaaccact 380 Sheffield et al, 1995
R: ctgccctcacttggacttaa
7p15 D7S3023 D F: tcaccccaggagatcagttgttgg 240 Keen et al, 1995
(MS0003) R: cagcaatgccaagattcaaaccag
7p15 SICA D F: aggcctggttccttactcag 110 Unpublished
R: aaggcatgcaaaatggaactgc
7p15 D7S683 D F: ttttaggcttatcaaacggg 260 Dib et al, 1996
R: ggtgtctgtctacatccaactg
7p13 D7S691 D F: gggtgattaatgcttgctta 130 Dib et al, 1996
R: gcttgattttccaacagg
7q22 D7S554 D F: gtctaattacccacatttccct 250 Dib et al, 1996
R: gttccatatttaaaagactcagtga
11p15 TH T F: gggtatctgggctctggggt 110 Hearne et al, 1992
R: ggtcacagggaacacagactcc
11p15 D11S1999 T F: tacatggcagcaggcatata 120 Sheffield et al, 1995
R: gagtaaacaagattgctagataggc
11p13 D11S1392 T F: ttgcatccatacggaaagtc 200 Sheffield et al, 1995
R: acatctgagacttgtagtagaaggc
16q21 D16S265 D F: ccagacatggcagtctcta 100 Weber et al, 1990
R: agtcctctgtgcactttgt
D = dinucleotide repeat, T = tetranucleotide repeat, F = forward primer, R = reverse primer. Physical mapping data from Chumakov et al (1995).microsatellites, with the exception of S1CA, which is a novel CA
repeat that we have isolated from a YAC clone that spans the t(1:7)
translocation (Reynolds et al, 1996). This polymorphic CA repeat
(observed heterozygosity 58%) maps between D7S683 and
D7S3023, to within 500 bp of the translocation breakpoint (Malik
and Reynolds, unpublished).
Seven of the 77 tumours (9%) showed LOH at 7p; these results
are summarized in Figure 1 and representative gels are shown in
Figures 2 and 3. The common region of LOH was between
D7S683 (7p15) and D7S517 (7p22), which covers the area
containing the t(1;7) breakpoint.
In addition we examined 58 WTs for homozygous deletions at
S1CA. All were positive for this marker, demonstrating that there
were no homozygous deletions in the region of the t(1;7) break-
point. Sixteen Wilms’ tumour DNAs have also been assessed by
Southern blotting for rearrangements using single-copy probes
derived from a cosmid clone that spans the t(1:7) translocation, but
no gross alterations were apparent within approximately 20 kb of
the breakpoint region (data not shown).
Clinical properties of tumours showing 7p LOH
Clinical data on age of presentation, sex, tumour stage, histology
and outcome are given in Table 2 for each of the tumours showing
7p LOH. A comparison of the clinical data for tumours with or
without 7p LOH is shown in Table 3 (clinical data were not avail-
able for all patients, see Materials and Methods). There did not
appear to be any striking differences in clinical features between
the two groups; the relapse rate was higher in 7p LOH tumours
(29% compared to 12%), but this difference was not statistically
significant.
Other genetic changes and cytogenetics
Cytogenetic analysis was successful in five out of the seven
tumours that had 7p LOH (Figure 1). Three of these (WT21, 57
and 73) had an isochromosome 7q, and one (WT59) showed
complete loss of one entire chromosome 7, all of which are
entirely consistent with the 7p LOH detected in these tumours
(Figure 1).
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Figure 1 Loss of heterozygosity at 7p in Wilms’ tumour. Loss of heterozygosity (LOH) was assessed using microsatellite markers on chromosomes 7, 11 and
16. Representative results of LOH studies are shown in Figures 2 and 3. Loss of imprinting (LOI) was assessed using a transcribed polymorphism in IGF2.
Karyotypes were determined by standard cytogenetic methods; no cells grew from WT30 and WT42. The common region of LOH on 7p was between D7S683
and D7S517 (7p15 to 7p22). 7p markers shown in italics were not used in this work but are mentioned in the discussion. LOH or LOI: n; no LOH or LOI:  8;
non-informative: n n; not done: (blank)Two patients with 7p LOH (WT30 and WT40) also showed
LOH at 11p, which in WT40 was associated with a homozygous
WT1 mutation (Figures 1 and 3). There was a lower frequency of
LOH at both 11p13 and 11p15 in the 7p LOH group when
compared with those WTs without 7p LOH (Table 3), but these
differences were not statistically significant. Both groups showed
similar levels of LOH at 16q (Table 3). One tumour with 7p LOH
(WT42) showed loss of imprinting at IGF2 (Figure 1).
Tumour progression and 7p LOH
In order to determine at which stage of tumour development 7p
changes occurred, we investigated LOH in other lesions associated
with the patients’ WTs.
The patient with WT40 had bilateral tumours; the data in Figure
1 came from the WT initially resected. DNA was subsequently
extracted by microdissection from the contralateral tumour and
amplified with primers for one informative microsatellite. The
second tumour did not show LOH at S1CA (7p15) but clearly did
show LOH at D11S1999 (11p15), whereas the original tumour
showed LOH at both 7p13 and 11p15 (Figure 3).
In WT57 the tumour contained a cystic nephroma-like area, and
it could be clearly seen that the cystic nephroma-like area also had
7p LOH (Figure 3).
WT21 also had associated rests but unfortunately all PCR reac-
tions were unsuccessful in that case. In WT59 there were perilobar
nephrogenic rests and one of these was microdissected to produce
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Figure 2 Examples of 7p LOH in Wilms’ tumour. Five examples of LOH at 7p are shown. DNA from normal kidney (N) or Wilms’ tumour (T) was amplified by
PCR with primers for various microsatellite markers on 7p and the products were resolved on non-denaturing polyacrylamide gels. The tumours analysed are
shown above the relevant lanes and the microsatellites are indicated on the left. A1 = larger allele, A2 = smaller allele. With D7S3023, stutter bands produce
two bands for each allele (both arrowed)
Table 2 Clinical data on Wilms’ tumours showing LOH at 7p
Age at
Tumour Sex diagnosis Stage Outcome Histology
(months)
WT21 M 65 I A Tb
WT30 M 42 II A T, Rh
WT40 F 13 V D S, Rhb
WT42 M 40 II A B
WT57 F 48 III Ra Tb
WT59 M 10 V A B, Rh
WT73 F 82 III R B
M = male, F = female, A = alive, D = dead, R = relapsed, T = triphasic,
S = stromal predominant, B = blastemal predominant, Rh = rhabdomyoblasts
present. aAlso developed therapy-induced acute myeloid leukaemia.
bHistology was of post-chemotherapy tumour.DNA. Unlike the tumour, the nephrogenic rest did not show LOH
at any of these 7p markers (S1CA; Figure 3, D7S795 and D7S691
not shown).
DISCUSSION
The results described in this paper demonstrate that in a large
series, 9% of Wilms’ tumours have loss of heterozygosity at 7p,
and that the common region of LOH includes the area involved in
the constitutional t(1;7) translocation which we have previously
mapped (Reynolds et al, 1996). This strongly suggests that there is
a novel tumour suppressor gene at 7p15 that is involved in the
development of a significant proportion of WTs.
Past and recent work from other laboratories support a role for 7p
in WT tumorigenesis. Several cytogenetic studies of sporadic WTs
have reported 7p deletions, translocations involving 7p, and isochro-
mosome 7q (Solis et al, 1988; Wang-Wuu et al, 1990; Kaneko et al,
1991; Sawyer et al, 1993; Peier et al, 1995; Riviera, 1995; Fletcher
and Renshaw, 1996; Miozzo et al, 1996; Steenman et al, 1997;
Lobbert et al, 1998). In some WTs, 7p changes have been found as
the sole cytogenetic abnormality (Solis et al, 1988; Wang-Wuu et al,
1990; Sawyer et al, 1993; Peier et al, 1995; Lobbert et al, 1998),
implying that these are unlikely to represent random changes.
Overall, reviews by several authors have implicated chromosome 7
cytogenetic abnormalities in up to 20% of WTs (Rivera et al, 1985;
Wang-Wuu et al, 1990; Kaneko et al, 1991; Austruy et al, 1995).
Our results are the largest study so far of 7p LOH in WT, and
our 9% LOH rate is very similar to the 10% (four out of 40)
reported recently by Grundy et al (1998), but less than the 27%
(three out of 11) found by Miozzo et al (1996). The common
region of LOH in our study was between D7S683 and D7S517
(7p15–7p22), which overlaps with the minimal LOH regions 
identified by Grundy et al (D7S503–D7S517) and Miozzo et al
(D7S506–D7S526) (Figure 1) (Miozzo et al, 1996; Grundy et al,
1998). However, the minimal regions defined in these latter reports
are separated by approximately 15 cM (Dib et al, 1996), with the
common region defined by Grundy et al being distal to that
reported by Miozzo et al. In addition, Grundy et al identified a
putative homozygous deletion at D7S507 (7p15/p21) in one
tumour (Grundy et al, 1998), which lies approximately 25 cM
distal to the constitutional t(1;7) breakpoint which we have
mapped in our WT patient (Reynolds et al, 1996). Thus it seems
likely that there may be two loci on 7p involved in the develop-
ment of Wilms’ tumour; one at 7p15 and another more distal. This
would agree with the reported locations of constitutional and
somatic translocation breakpoints, which have been identified at
both 7p15 (Miozzo et al, 1996; Reynolds et al, 1996) and 7p22
(Rivera, 1995; Lobbert et al, 1998).
We have not identified any particular characteristics associated
with 7p LOH (Tables 2 and 3). In contrast, Grundy et al (1998)
have suggested that tumours with 7p abnormalities tend to be of
early onset and of high stage. Clearly larger numbers of tumours
need to be studied, but if there are two WT loci on 7p, then distinct
phenotypes may be associated with each locus, complicating the
analysis of clinical data when genetic abnormalities have only
been defined by LOH.
In four of the WTs with 7p LOH, we have found other associ-
ated genetic abnormalities (Figure 1), three of which involve 11p
(WT1 mutation with 11p LOH, 11p LOH and loss of imprinting of
IGF2). Grundy et al (1998) reported that 11p LOH had been previ-
ously identified in one of their WTs with 7p LOH, and others have
found chromosome 7 cytogenetic abnormalities in association
with a chromosome 11 deletion (Wang-Wuu et al, 1990), and with
a germline WT1 mutation and 11p LOH (Lobbert et al, 1998). Thus
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Figure 3 LOH studies in other lesions associated with Wilms’ tumour. DNA
was extracted from normal kidney (N) or Wilms’ tumour (T) or from
microdissections of associated lesions: a second WT (T2; WT40), an area of
cystic nephroma (C; WT57), or a perilobar nephrogenic rest (R; WT59).
Other details as in Figure 1. In WT40 LOH occurred at 7p15 only in the first
tumour (T), not in the second (T2), but both had LOH at 11p15. In WT57 both
the cystic nephroma area (C) and the Wilms’ tumour (T) showed LOH at
7p15. In WT59 the tumour (T) had LOH at 7p, whereas the nephrogenic rest
(R) showed no loss
Table 3 Comparison of clinical data and other LOH data for 7p LOH and non-LOH Wilms’ tumours
Sex (no.) Mean age at  Stage distribution Outcome (no.) Other LOH (no. with LOH/no.
(%) diagnosis (no.) (%) (%) informative) (%)
7 p Number
LOH of cases Male Female (months) I II III IV V Relapsed Died 11p13 11p15 16q
No 52 22 30 42.6 12 16 10 8 6 6 9 13/28 20/44 6/36
42% 58% 23% 31% 19% 15% 12% 12% 17% 46% 45% 17%
Yes 7 4 3 42.9 1 2 2 0 2 2 1 2/6a 2/7 1/5
57% 43% 14% 29% 29% 0% 29% 29% 14% 33% 29% 20%
aIncludes tumour with homozygous WT1 mutation (WT40).it appears that 7p LOH is an event that usually occurs in concert
with other genetic abnormalities.
These results suggest that chromosome 7 changes are important
in WT development, but that they may be insufficient in them-
selves for malignant transformation. In order to determine at
which stage of WT development 7p LOH was involved, we exam-
ined other lesions associated with the tumours (Figure 3). In
WT57, a cystic nephroma-like area showed 7p LOH, as did the
bulk of the tumour. This supports the contention that cystic
nephroma is closely related to Wilms’ tumour, and that cystic
nephroma-like areas within a WT should be regarded as a part of
the tumour, or possibly a precursor lesion (Charles et al, 1998b). In
contrast, in WT40, where there were bilateral tumours, the second
contralateral tumour did not show 7p LOH, whereas both tumours
had LOH at 11p15. The first tumour from WT40 had previously
been shown to have a homozygous WT1 mutation (Miyagawa et
al, 1998), and we have now shown that the mutation is germline in
this patient (data not shown). From the 11p LOH results (Figure 3)
we would suggest that the second tumour was also homozygous
for the WT1 mutation. It therefore appears that in the case of
WT40, LOH at 7p was a late event that only occurred in one of the
bilateral tumours, with the development of homozygosity for a
WT1 mutation being the initiating event in both tumours. In
WT59, 7p LOH was found only in the tumour and not in an asso-
ciated nephrogenic rest (Figure 3). Nephrogenic rests are thought
to be premalignant lesions from which malignant Wilms’ tumours
develop (Beckwith et al, 1990), therefore the WT59 result also
suggests that 7p LOH was a relatively late event in the develop-
ment of that tumour.
Knudson and Strong originally proposed that two rate-limiting
events were necessary for WT development, although this did not
preclude other non-rate-limiting genetic events being involved
(Knudson and Strong, 1972). Park et al have demonstrated that
homozygous WT1 mutations can be found in nephrogenic rests
(Park et al, 1993) and our recent studies have confirmed this in two
other cases, and shown that in most WTs showing 11p LOH, LOH
also occurs in associated nephrogenic rests (Charles et al, 1998a).
Thus it is clear that whilst WT1 mutations can initiate WT devel-
opment, other events may be required for progression to a fully
malignant tumour. The results presented in this paper implicate 7p
genes in this progression, because some of the tumours with
7p LOH also had 11p alterations, and in others we have found
that 7p LOH appears to be a relatively late event.
However, Steenman et al used comparative genomic hybridiza-
tion to show in one case of WT that deletion of 7p was found in
both the tumour and in an associated nephrogenic rest, although
loss of 1p was present exclusively in the tumour (Steenman et al,
1997). Together with the germline translocations at 7p (Hewitt et
al, 1991; Rivera, 1995), these results suggest that 7p alterations
can be initiating events in some WTs. WT development may there-
fore have a preferred order of genetic changes, but it is the accu-
mulation of events which is critical for the development of
malignancy, as observed in more complex multistage cancers
(Fearon and Vogelstein, 1990).
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